This inventor holds 5 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Fox Chase Cancer Center, Immunitybio, Inc., Institute for Cancer Research. Active years: 2009-2025.
Company Filing History:
4 out of 81 
1 out of 62 
1 out of 69 
Years Active: 2009-2025
Title: The Innovative Contributions of Kerry S. Campbell
Introduction
Kerry S. Campbell is a notable inventor based in Wyncote, Pennsylvania, recognized for his significant contributions to cancer research and treatment. With a total of five patents to his name, Campbell has made strides in the field of genetically modified cell therapies.
Latest Patents
Among his latest patents is the invention titled "Genetically modified NK-92 cells having a safety switch." This invention focuses on the treatment of subjects with cancer by administering a monoclonal antibody alongside NK-92 cells that express an Fc receptor. Another significant patent is for "Genetically modified human natural killer cell lines." This invention provides a modified NK-92 cell that expresses an Fc receptor on its surface, such as CD16, and can be further enhanced to express accessory signaling proteins or cytokines like interleukin-2.
Career Highlights
Kerry S. Campbell has worked with esteemed organizations such as the Fox Chase Cancer Center and the Institute for Cancer Research. His work has been pivotal in advancing the understanding and treatment of cancer through innovative cellular therapies.
Collaborations
Some of his notable coworkers include Tien Lee and Hans G. Klingemann, who have collaborated with Campbell on various research projects.
Conclusion
Kerry S. Campbell's innovative work in the field of cancer treatment through genetically modified cell therapies showcases his dedication to advancing medical science. His contributions continue to impact the landscape of cancer research and therapy.